Technical Coverage on Pharma Stocks -- GlaxoSmithKline, TherapeuticsMD, AstraZeneca, Zogenix, and Novartis

Tue Jul 22, 2014 9:10am EDT

* Reuters is not responsible for the content in this press release.

Technical Coverage on Pharma Stocks -- GlaxoSmithKline, TherapeuticsMD, AstraZeneca, Zogenix, and Novartis

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

LONDON, July 22, 2014 /PRNewswire/ --

On Monday, July 21, 2014, the NASDAQ Composite ended at 4,424.70, down 0.17%, the Dow Jones Industrial Average declined 0.28%, to finish the day at 17,051.73, and the S&P 500 closed at 1,973.63, down 0.23%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 707.91, down 0.39%, while the index has advanced 6.22% in the previous three months. Investor-Edge has initiated coverage on the following equities: GlaxoSmithKline PLC (NYSE: GSK), TherapeuticsMD Inc. (NYSE MKT: TXMD), AstraZeneca PLC (NYSE: AZN), Zogenix Inc. (NASDAQ: ZGNX), and Novartis AG (NYSE: NVS). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

GlaxoSmithKline PLC's stock finished the Monday's session 0.61% lower at $53.39. A total of 2.05 million shares were traded, which was below its three months average volume of 2.39 million shares. The stock moved between $53.19 and $53.48 during the session. Over the last three trading sessions and the previous three months, GlaxoSmithKline PLC's shares have gained 0.15% and 0.51%, respectively. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $54.19 is greater than its 200-day moving average of $53.40. GlaxoSmithKline PLC's stock has a Relative Strength Index (RSI) of 48.60. Sign up and read the free notes on GSK at:

http://www.Investor-Edge.com/GSK-22Jul2014

On Monday, shares in TherapeuticsMD Inc. fluctuated between $4.15 and $4.57 before ending the session 5.85% higher at $4.52. TherapeuticsMD Inc.'s stock reported a trading volume of 1.63 million shares, below its three months average volume of 1.75 million shares. Although, TherapeuticsMD Inc.'s shares have advanced 7.11% in the previous three trading sessions, it has declined 8.13% in the last three months and 13.24% on YTD basis. The stock is trading above its 50-day moving average of $4.36, while the 50-day moving average is below TherapeuticsMD Inc.'s 200-day moving average of $5.02. Moreover, shares of the company have an RSI of 45.01. The complimentary notes on TXMD can be downloaded as in PDF format at:

http://www.Investor-Edge.com/TXMD-22Jul2014

AstraZeneca PLC's stock edged 0.66% higher, to close the day at $75.01. The stock recorded a trading volume of 1.06 million shares, much below its three months average volume of 5.41 million shares. The stock oscillated between $74.49 and $75.07 during the session. Over the last three trading sessions and over the past three months, AstraZeneca PLC's shares have gained 0.66% and 8.55%, respectively. Further, the stock has advanced 26.34% since the start of this year. The stock is trading above its 50-day and 200-day moving averages of $74.46 and $64.46, respectively. Additionally, the stock has an RSI of 50.58. Register for free on Investor-Edge and access the latest research on AZN at:

http://www.Investor-Edge.com/AZN-22Jul2014

On Monday, shares in Zogenix Inc. recorded a trading volume of 0.96 million shares, lower than its three months average volume of 2.54 million shares. The stock ended the day at $1.63, which was 0.61% below its previous day's closing of $1.64, and registered an intraday range of $1.60 and $1.66. Zogenix Inc.'s shares have lost 0.61% in the previous three trading sessions, 15.98% in the last one month and 52.62% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $1.96 and $2.96, respectively. Furthermore, shares of the company have an RSI of 37.58. The complete research on ZGNX is available for free at:

http://www.Investor-Edge.com/ZGNX-22Jul2014

Novartis AG's stock finished the Monday's session 0.26% lower at $88.59. A total of 1.04 million shares were traded, which was below its three months average volume of 1.59 million shares. The stock moved between $88.38 and $88.93 during the session. Over the last three months and since the beginning of this year, Novartis AG's shares have gained 3.66% and 10.21%, respectively. However, the company's stock has declined 1.61% in the previous three trading sessions. The stock is trading above its 200-day moving average of $82.75, while the 200-day moving average is below Novartis AG's 50-day moving average of $89.78. The stock has an RSI of 41.61. Free in depth research on NVS is available at:

http://www.Investor-Edge.com/NVS-22Jul2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge